What is the BPC-157 and TB-500 blend?

A single vial holding both compounds co-lyophilised in a fixed ratio. BPC-157 is a pentadecapeptide originally identified in gastric juice; TB-500 is a synthetic fragment of thymosin beta 4. The pairing is common in recovery contexts because one is studied mostly for local tissue repair and the other for systemic actin regulation and cell migration.

Why does a blend need a different calculator than a single peptide?

Because you cannot dose the components independently. The vial has one ratio, so one draw volume sets both amounts at once. If the ratio in the vial does not match the ratio of the two compounds’ own targets, one of them lands off target. A single-peptide calculator has no way to surface that; the titration table on this page does, per phase and per experience level.

How is the draw volume decided?

It is the largest volume at which neither component passes its own upper bound in the engine dose table. The page names which component set the limit and why. That is a deliberately conservative rule: a blend ratio can quietly push one compound high while the other is still short, and the ceiling is the figure the engine will not cross.

Does body weight change the dose?

For TB-500, yes: the engine catalog flags it weight sensitive and carries a per-kilogram factor, so the weight you enter sets its target. For BPC-157, no. The catalog does not flag it weight sensitive and the dose calculator applies no weight scaling of its own, so the tool leaves it alone rather than inventing a rule. The page states which components move and which do not.

What does the experience level input actually change?

It selects a different row in the engine dose table, which changes the opening dose, the standard dose, the upper dose and the ceiling for every component at once. It is not a cosmetic filter. It is the same experience banding the protocol engine uses when it sets a dose envelope.

How much bacteriostatic water should I add?

There is no single right answer. More water gives a more dilute solution, which spreads a given amount across more syringe units and is easier to measure precisely. Less water concentrates it. Change the water volume in the calculator and every table updates, so you can pick the volume that puts your draw in a comfortable part of the syringe.

Is the blend the same thing as the Wolverine stack?

Same two compounds, different presentation, and the difference is practical. A blend is co-mixed in one vial, so it forces one draw volume and one schedule. A stack is two separate vials, so each compound can hold its own target and its own frequency. The Wolverine stack calculator on this site works the separate-vial case.

How long is a cycle, and how many vials does it take?

The cycle length on the supplies table is read from the engine catalog’s cycling data for the components, taking the shortest on-period, because a shared vial cannot be cycled per component. Multiply that by the administrations per week from the dose table and the tool returns vials, syringes and bottles of bacteriostatic water.

Is this calculator free?

Yes. No account, no paywall, no usage limit. The protocol engine behind it is a separate product, but the calculator is open.

Does Klarovel sell this blend?

No. Klarovel is the protocol layer: a questionnaire, a deterministic rules engine and a generated protocol. Any product is fulfilled by partner suppliers, not by Klarovel. This page exists because the arithmetic of a fixed-ratio vial is genuinely hard to do in your head, not to move a product.

Is this medical advice?

No. It is arithmetic over published dose data, presented as a reference. It is not a prescription and not a recommendation to use any compound. Discuss peptide use with a qualified clinician.

BPC-157 and TB-500 blend calculator

One vial, two compounds, one draw volume. This calculator splits a co-mixed BPC-157 and TB-500 vial into what each component actually delivers at every draw, then checks that draw against each compound’s own upper bound.

Set your vial composition, water volume, experience level and body weight. The per-component breakdown, the three-phase titration table and the supplies plan all recompute. Every dose figure is read from the Klarovel engine’s dose table, never typed into the page.

Vial composition

Vial contents, not doses. Confirm against the label on the vial in front of you before you mix.

Bacteriostatic water added

Experience with injectable peptides

Body weight

Age 65 or over

Standard phase, single shared draw

9.0 units

0.09 ml on a 100-unit insulin syringe

BPC-157

on target

300 mcg

target 300 mcg, ceiling 500 mcg

TB-500 (Thymosin Beta-4)

under target

0.3 mg

target 2.4 mg, ceiling 2.5 mg

The draw is set by BPC-157, which reaches its target first. Every other component is read off the same draw because a blend has one ratio.

Per-component breakdown at every draw volume

What each draw volume actually delivers per component at 3 ml of bacteriostatic water and the vial composition selected above. These are mathematical breakdowns of the vial, not dose recommendations. The targets and ceilings are in the titration table below.

Per-component amount delivered at each insulin syringe draw volume
Draw	Volume	BPC-157	TB-500 (Thymosin Beta-4)
2 units	0.02 ml	66.7 mcg	0.067 mg
4 units	0.04 ml	133.3 mcg	0.133 mg
5 units	0.05 ml	166.7 mcg	0.167 mg
6 units	0.06 ml	200 mcg	0.2 mg
8 units	0.08 ml	266.7 mcg	0.267 mg
10 units	0.1 ml	333.3 mcg	0.333 mg
12 units	0.12 ml	400 mcg	0.4 mg
15 units	0.15 ml	500 mcg	0.5 mg
20 units	0.2 ml	666.7 mcg	0.667 mg
25 units	0.25 ml	833.3 mcg	0.833 mg
30 units	0.3 ml	1000 mcg	1 mg
40 units	0.4 ml	1333.3 mcg	1.333 mg
50 units	0.5 ml	1666.7 mcg	1.667 mg

Arithmetic over the vial composition and your water volume. The display unit per component is the unit that component's row declares in the engine dose table.

Phase by phase titration

Three phases, in the order the engine escalates a dose: opening, standard, then upper. Every figure below is the beginner row of the engine dose table for that component, after the modifiers your inputs trigger. Change experience level, weight or age above and the whole table recomputes.

Phase 1, opening dose

draw 7.5 units

Phase 1, opening dose per component
Component	Delivered	Target	Draw for target	Ceiling
BPC-157	250 mcg	250 mcg	7.5 units	500 mcg
TB-500 (Thymosin Beta-4)	0.25 mg	2.4 mg	72.0 units	2.5 mg

The components' own targets are reached 9.6x apart in draw volume, so one draw cannot satisfy them all. TB-500 (Thymosin Beta-4) lands under target at this draw. Reaching that target would mean drawing further and pushing another component past its ceiling, which is why the volume stops here.

TB-500 (Thymosin Beta-4) is weight sensitive in the catalog at 0.03 mg/kg, so 80 kg sets the target rather than the fixed phase figure.

Phase 2, standard dose

draw 9.0 units

Phase 2, standard dose per component
Component	Delivered	Target	Draw for target	Ceiling
BPC-157	300 mcg	300 mcg	9.0 units	500 mcg
TB-500 (Thymosin Beta-4)	0.3 mg	2.4 mg	72.0 units	2.5 mg

The components' own targets are reached 8x apart in draw volume, so one draw cannot satisfy them all. TB-500 (Thymosin Beta-4) lands under target at this draw. Reaching that target would mean drawing further and pushing another component past its ceiling, which is why the volume stops here.

TB-500 (Thymosin Beta-4) is weight sensitive in the catalog at 0.03 mg/kg, so 80 kg sets the target rather than the fixed phase figure.

Phase 3, upper dose

draw 12.0 units

Phase 3, upper dose per component
Component	Delivered	Target	Draw for target	Ceiling
BPC-157	400 mcg	400 mcg	12.0 units	500 mcg
TB-500 (Thymosin Beta-4)	0.4 mg	2.4 mg	72.0 units	2.5 mg

The components' own targets are reached 6x apart in draw volume, so one draw cannot satisfy them all. TB-500 (Thymosin Beta-4) lands under target at this draw. Reaching that target would mean drawing further and pushing another component past its ceiling, which is why the volume stops here.

TB-500 (Thymosin Beta-4) is weight sensitive in the catalog at 0.03 mg/kg, so 80 kg sets the target rather than the fixed phase figure.

Targets, upper bounds and ceilings read from dose_protocols, the engine's dose table. Weight scaling applies only where PEPTIDE_CATALOG flags a component weight sensitive. The 0.75x age reduction is the engine's own contraindication rule for age 65 and over.

What your body weight does, and does not, change

Weight sensitive: TB-500 (Thymosin Beta-4) at 0.03 mg/kg. The engine catalog carries a per-kilogram factor for this component, so the weight you entered sets the target directly and is then held inside the beginner ceiling.

Not weight sensitive: BPC-157. The catalog does not flag this component weight sensitive and the dose calculator applies no weight scaling of its own, so changing the weight field does not move its target. Scaling every compound by body mass would be an invention, so the tool does not do it.

Supplies for one cycle

One on-cycle runs 12 weeks, followed by 4 weeks off.

Administrations per week

Options come from the components' own frequency strings: BPC-157 is once to twice daily, TB-500 (Thymosin Beta-4) is twice weekly. Where those disagree there is no single correct value, so the default is the most conservative one the data supports.

Bacteriostatic water bottle size

Supplies required for one on-cycle
Cycle length	12 weeks
Administrations per week	2
Total administrations	24
Vials	1
Insulin syringes	24 (30-unit holds the draw)
Bacteriostatic water	3 ml, 1 bottle of 10 ml

Cycle length from PEPTIDE_CATALOG cycling data. Administrations per week derived from the frequency string on each component's dose row. Vial and syringe counts are arithmetic over your draw volume and water volume.

The components' sourced frequencies do not overlap: BPC-157 is once to twice daily, TB-500 (Thymosin Beta-4) is twice weekly. A single vial forces one schedule, so no frequency satisfies every component's row. That is a real limitation of a fixed-ratio blend and the reason a protocol would run these as separate vials.

Component reference

Route, timing, frequency and cycling per component, read from the engine catalog.

Per-component administration and cycling reference
Component	Route	Timing	Frequency	Cycle	Loading phase
BPC-157	subcutaneous	Any time	once to twice daily	12 on / 4 off	None
TB-500 (Thymosin Beta-4)	subcutaneous	Any time	twice weekly	12 on / 4 off	4 weeks at 2x

Route, timing and cycling from PEPTIDE_CATALOG. Frequency from the beginner row of dose_protocols.

What a fixed blend cannot do, stated plainly

A blend is one ratio in one vial. There is exactly one draw volume, and it has to serve every component at once. When the ratio does not match the ratio of the components' own targets, something has to give: either a component lands under its target, or another is pushed toward its ceiling. The table above says which, for your inputs, rather than printing a single volume and leaving it unresolved.

Contraindications are the second limit. A protocol can drop one compound and keep the rest. A blend cannot, because the compounds share a vial. If a health condition rules out one component, it rules out the vial.

A Klarovel protocol is built from your health data. Blood work is optional and sharpens the result, but it never gates it. The engine resolves contraindications, sets the dose envelope by experience level, removes incompatible pairs and sets the cycling schedule. That is the difference between a calculator and a protocol.

Save your reconstitution. Get the protocol it belongs in.

Free founding-member access while spots last. We'll send your reconstitution + a link to claim your slot.

Questions

What is the BPC-157 and TB-500 blend?: A single vial holding both compounds co-lyophilised in a fixed ratio. BPC-157 is a pentadecapeptide originally identified in gastric juice; TB-500 is a synthetic fragment of thymosin beta 4. The pairing is common in recovery contexts because one is studied mostly for local tissue repair and the other for systemic actin regulation and cell migration.
Why does a blend need a different calculator than a single peptide?: Because you cannot dose the components independently. The vial has one ratio, so one draw volume sets both amounts at once. If the ratio in the vial does not match the ratio of the two compounds’ own targets, one of them lands off target. A single-peptide calculator has no way to surface that; the titration table on this page does, per phase and per experience level.
How is the draw volume decided?: It is the largest volume at which neither component passes its own upper bound in the engine dose table. The page names which component set the limit and why. That is a deliberately conservative rule: a blend ratio can quietly push one compound high while the other is still short, and the ceiling is the figure the engine will not cross.
Does body weight change the dose?: For TB-500, yes: the engine catalog flags it weight sensitive and carries a per-kilogram factor, so the weight you enter sets its target. For BPC-157, no. The catalog does not flag it weight sensitive and the dose calculator applies no weight scaling of its own, so the tool leaves it alone rather than inventing a rule. The page states which components move and which do not.
What does the experience level input actually change?: It selects a different row in the engine dose table, which changes the opening dose, the standard dose, the upper dose and the ceiling for every component at once. It is not a cosmetic filter. It is the same experience banding the protocol engine uses when it sets a dose envelope.
How much bacteriostatic water should I add?: There is no single right answer. More water gives a more dilute solution, which spreads a given amount across more syringe units and is easier to measure precisely. Less water concentrates it. Change the water volume in the calculator and every table updates, so you can pick the volume that puts your draw in a comfortable part of the syringe.
Is the blend the same thing as the Wolverine stack?: Same two compounds, different presentation, and the difference is practical. A blend is co-mixed in one vial, so it forces one draw volume and one schedule. A stack is two separate vials, so each compound can hold its own target and its own frequency. The Wolverine stack calculator on this site works the separate-vial case.
How long is a cycle, and how many vials does it take?: The cycle length on the supplies table is read from the engine catalog’s cycling data for the components, taking the shortest on-period, because a shared vial cannot be cycled per component. Multiply that by the administrations per week from the dose table and the tool returns vials, syringes and bottles of bacteriostatic water.
Is this calculator free?: Yes. No account, no paywall, no usage limit. The protocol engine behind it is a separate product, but the calculator is open.
Does Klarovel sell this blend?: No. Klarovel is the protocol layer: a questionnaire, a deterministic rules engine and a generated protocol. Any product is fulfilled by partner suppliers, not by Klarovel. This page exists because the arithmetic of a fixed-ratio vial is genuinely hard to do in your head, not to move a product.
Is this medical advice?: No. It is arithmetic over published dose data, presented as a reference. It is not a prescription and not a recommendation to use any compound. Discuss peptide use with a qualified clinician.

Other blend calculators

Same engine, different vial. Pick the page that matches what you actually have in front of you: the component list and the ratio change the arithmetic completely.

References

These papers cover the mechanism and clinical context of BPC-157 and thymosin beta 4, the parent protein TB-500 is a fragment of.

The dose figures on this page are not sourced from these papers. They are read from the Klarovel engine's own dose table, which is cited inline wherever a number appears. These references cover mechanism, pharmacology and clinical context.

16 references, every identifier resolved against NCBI on 2026-07-30. Per peptide, a relevance-sorted esearch was run and every returned id was resolved through esummary. Any id esummary could not resolve was dropped, and any record carrying the 'Retracted Publication' pubtype was dropped. Titles, journals, years and first authors below are the values esummary returned, not authored text. One retracted record was dropped: PMID 37696839 (thymosin beta 4 query).

1.Chang CH et al. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol (1985) 2011. PMID 21030672
2.Seiwerth S et al. Stable Gastric Pentadecapeptide BPC 157 and Wound Healing. Front Pharmacol 2021. PMID 34267654 PMC8275860
3.Gwyer D et al. Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell Tissue Res 2019. PMID 30915550
4.Józwiak M et al. Multifunctionality and Possible Medical Application of the BPC 157 Peptide-Literature and Patent Review. Pharmaceuticals (Basel) 2025. PMID 40005999 PMC11859134
5.Vasireddi N et al. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS J 2025. PMID 40756949 PMC12313605
6.Lee E et al. Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study. Altern Ther Health Med 2025. PMID 40131143
7.McGuire FP et al. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Curr Rev Musculoskelet Med 2025. PMID 40789979 PMC12446177
8.Sikiric P et al. The Stable Gastric Pentadecapeptide BPC 157 Pleiotropic Beneficial Activity and Its Possible Relations with Neurotransmitter Activity. Pharmaceuticals (Basel) 2024. PMID 38675421 PMC11053547
9.Goldstein AL et al. Thymosin β4: a multi-functional regenerative peptide. Basic properties and clinical applications. Expert Opin Biol Ther 2012. PMID 22074294
10.Kleinman HK et al. Thymosin β4 Promotes Dermal Healing. Vitam Horm 2016. PMID 27450738
11.Pipes GT et al. Cardioprotection by Thymosin Beta 4. Vitam Horm 2016. PMID 27450736
12.Smart N et al. Thymosin beta-4 is essential for coronary vessel development and promotes neovascularization via adult epicardium. Ann N Y Acad Sci 2007. PMID 17495252
13.Zhang Y et al. Recombinant human thymosin beta 4 improves ischemic cardiac dysfunction in mice and patients with acute ST-segment elevation myocardial infarction after reperfusion. Cardiovasc Res 2025. PMID 41229390
14.Tan WKY et al. Sources of variability in quantifying circulating thymosin beta-4: literature review and recommendations. Expert Opin Biol Ther 2018. PMID 29502471
15.Nachmias VT et al. Small actin-binding proteins: the beta-thymosin family. Curr Opin Cell Biol 1993. PMID 8448031
16.Mendias CL et al. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. Sports Med 2026. PMID 41966639

Beyond the arithmetic

A protocol resolves what a blend cannot.

The Klarovel engine reads your health data, resolves contraindications, sets the dose envelope by experience level, removes incompatible pairs and builds the cycling and monitoring schedule. Blood work is optional and sharpens the result. It is never required.